In particular, angiotensin receptor–neprilysin inhibitor (ARNi) showed no increase in AF incidence and consistent efficacy across AF patients in the PARADIGM-HF trial [7], and sodium–glucose transport protein 2 inhibitors (SGLT2is) proved consistent beneficial effects in patients with AF in most RCTs [8,9,10,11]. This evidence concerns the gene MME and atrial fibrillation.